NCT06280209
Duchenne Muscular Dystrophy
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The purpose of this study is to test the safety and tolerability of BMN 351 in participants with Duchenne Muscular Dystrophy (DMD) with a genetic mutation amenable to exon 51 skipping.
Male
4 Years to 10 Years
No
BMN 351
Phase 1/Phase 2
Interventional
18
2024-01-03
2024-12-05
Milan, , Italy
Rome, , Italy
Leiden, , Netherlands
Barcelona, , Spain
Sevilla, , Spain
Istanbul, , Turkey
London, , United Kingdom
*required fields
"*" indicates required fields